SR9009 – Stenabolic

When your protocol calls for a clean, well-characterized tool to probe the circadian clock, mitochondrial biogenesis and fat oxidation, SR9009 – Stenabolic is the compound serious labs order with confidence. Helixx supplies premium, Canadian-sourced SR9009 – Stenabolic Canada material backed by third-party verification and fast domestic shipping, giving researchers a dependable REV-ERB agonist whose metabolic effects are among the most studied in the endurance and circadian-biology literature.¹ For laboratory, research and educational use only; not for human consumption.

What Is SR9009 – Stenabolic?

SR9009 (Stenabolic) is a synthetic small-molecule agonist of the nuclear heme receptors REV-ERBalpha and REV-ERBbeta (NR1D1/NR1D2). Despite being marketed alongside SARMs, it is not a true SARM and has no androgen receptor binding activity whatsoever. Instead it acts on a core component of the biological clock, which is why it is studied for endurance, energy expenditure and lipid metabolism rather than direct muscle-tissue androgen signalling. A landmark 2012 study first introduced it as a probe for manipulating circadian behaviour and metabolism.¹ Within the Canadian SARMs and research-chemical market, SR9009 is best understood as a metabolic and circadian research tool compound rather than an anabolic agent.

How SR9009 Works

SR9009 binds directly to REV-ERBalpha (measured binding affinity of roughly 800 nM) and activates the transcriptional-repressor arm of the core circadian clock. In doing so it suppresses BMAL1/Arntl and other clock and clock-controlled genes, and represses REV-ERB target genes that govern lipid and glucose metabolism, gluconeogenesis, adipogenesis and inflammatory macrophage responses.¹ In skeletal muscle, REV-ERB activation promotes mitochondrial biogenesis and oxidative metabolism while modulating autophagy through the LKB1-AMPK-SIRT1-PGC-1alpha pathway; in rodent models this raised mitochondrial content, oxidative respiration and running capacity.² Two things shape how it gets used at the bench. Its oral bioavailability is poor (roughly 2% in mice) and its half-life is short, so it behaves as a research tool compound rather than a drug-like agent. It also has confirmed REV-ERB-independent (off-target) actions, so not every effect can be pinned on its intended receptor.³

What the Research Shows

• Circadian and metabolic reprogramming. In diet-induced obese mice, SR9009 produced weight loss driven by decreased fat mass, increased oxygen consumption and energy expenditure, and lowered plasma lipids (a 47% decrease in total cholesterol and 12% decrease in triglycerides).¹
• Mitochondrial and exercise capacity. Pharmacological REV-ERBalpha activation increased mitochondrial content, oxidative respiration and running/exercise capacity in mice, while REV-ERBalpha deficiency impaired mitochondrial function and exercise output.²
• Low-dose metabolic benefit. Chronic low-dose SR9009 over eight weeks reduced weight gain, white fat mass and insulin resistance in circadian-disrupted mice via adipogenesis modulation, without major changes to overall energy homeostasis.⁴
• Off-target activity. SR9009 decreased cell viability, rewired cellular metabolism and altered gene transcription even in cells genetically lacking both REV-ERBalpha and REV-ERBbeta, proving significant activity independent of its intended target.³

Researchers frequently compare SR9009 with the PPAR-delta agonist Cardarine – GW-501516 in endurance and metabolism studies, and may bench it alongside androgen-receptor SARMs such as LGD-4033 – Ligandrol and RAD 140 – Testolone, or against metabolic peptides like MOTS-c, to isolate REV-ERB-specific effects.

Chemical Properties

Research Protocols & Handling

SR9009 is supplied strictly as a research chemical for in vitro and preclinical laboratory investigation and educational reference. It is not intended for human or veterinary use, consumption or administration of any kind. Because its oral bioavailability is poor and its half-life short, exposure by non-injectable routes runs low and erratic, a key consideration when designing rodent and cell-based study models. Store lyophilized or powdered material sealed, protected from light and moisture, at -20 degrees C for long-term stability; where a compound is reconstituted for benchwork, use an appropriate laboratory solvent, aliquot to minimize freeze-thaw cycles, and keep working solutions refrigerated and used promptly. All handling should follow standard laboratory safety practice under qualified supervision.

Potential Side Effects & Safety

References

Peer-reviewed and authoritative sources cited above. Helixx supplies research materials for laboratory and educational use only; citations are provided for independent verification, not as medical guidance.

1. Solt LA, Wang Y, Banerjee S, et al. Regulation of circadian behavior and metabolism by synthetic REV-ERB agonists. Nature. 2012;485(7396):62-68. PMID: 22460951.
2. Woldt E, Sebti Y, Solt LA, et al. Rev-erb-alpha modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat Med. 2013;19(8):1039-1046. PMID: 23852339.
3. Dierickx P, Emmett MJ, Jiang C, et al. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. Proc Natl Acad Sci USA. 2019;116(25):12147-12152. PMID: 31127047.
4. Chronic low-dose REV-ERBs agonist SR9009 mitigates constant light-induced weight gain and insulin resistance via adipogenesis modulation. 2025. PMC12277734.